Zhejiang Shapuaisi PharmaceuticalLtd Valuation

Is 603168 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 603168 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 603168 (CN¥7.92) is trading above our estimate of fair value (CN¥0.46)

Significantly Below Fair Value: 603168 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 603168?

Key metric: As 603168 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 603168. This is calculated by dividing 603168's market cap by their current revenue.
What is 603168's PS Ratio?
PS Ratio	5.9x
Sales	CN¥505.58m
Market Cap	CN¥2.98b

603168 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	6x
Enterprise Value/EBITDA	-404.5x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 603168's PS Ratio compare to its peers?

The above table shows the PS ratio for 603168 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	6x
301201 ChengDa Pharmaceuticals	8.3x	n/a	CN¥3.3b
603538 Ningbo Menovo Pharmaceutical	2.4x	27.8%	CN¥2.9b
301111 Guangdong Lifestrong Pharmacy	9.9x	n/a	CN¥3.2b
603079 Zhejiang Shengda Bio-Pharm	3.3x	n/a	CN¥2.6b
603168 Zhejiang Shapuaisi PharmaceuticalLtd	5.9x	n/a	CN¥3.0b

Price-To-Sales vs Peers: 603168 is good value based on its Price-To-Sales Ratio (5.9x) compared to the peer average (6x).

Price to Sales Ratio vs Industry

How does 603168's PS Ratio compare vs other companies in the CN Pharmaceuticals Industry?

6 Companies	Price / Sales	Estimated Growth	Market Cap
600664 Harbin Pharmaceutical Group	0.6x	n/a	US$1.29b
000411 Zhejiang Int'l GroupLtd	0.2x	n/a	US$787.82m
000153 Anhui Fengyuan Pharmaceutical	0.7x	n/a	US$411.84m
600781 FUREN Group PharmaceuticalLtd	0.3x	n/a	US$66.91m

6 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 603168 is expensive based on its Price-To-Sales Ratio (5.9x) compared to the CN Pharmaceuticals industry average (3.6x).

Price to Sales Ratio vs Fair Ratio

What is 603168's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

603168 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	5.9x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 603168's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Sichuan Kelun Pharmaceutical

CN¥49.3b

Researches, develops, manufactures, distributes, and sells pharmaceutical products in China.

2422

CN¥32.66

2.6%

14.2%

Dong-E-E-JiaoLtd

CN¥36.7b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥58.18

-0.4%

15.5%

China Resources Double-Crane PharmaceuticalLtd

CN¥21.2b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥21.11

-5.1%

14.5%